{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:52:07Z","timestamp":1759452727250,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.eclinm.2025.103211","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T22:41:54Z","timestamp":1745793714000},"page":"103211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mitoxantrone in combination with clofarabine (MITCL) in children, adolescents and young adults with relapsed\/refractory acute leukaemia: final results of a phase I\/II trial"],"prefix":"10.1016","volume":"83","author":[{"given":"Jessica","family":"Hochberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0668-7965","authenticated-orcid":false,"given":"Javier","family":"Oesterheld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliza","family":"Gardenswartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allyson","family":"Flower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana","family":"Klejmont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackie","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Borowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Loken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2075-434X","authenticated-orcid":false,"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103211_bib1","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I treat relapsed acute lymphoblastic leukemia in the pediatric population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2025.103211_bib2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2025.103211_bib3","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/S2352-3026(19)30003-1","article-title":"Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial","volume":"6","author":"Parker","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.eclinm.2025.103211_bib4","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.eclinm.2025.103211_bib5","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/bloodadvances.2021005579","article-title":"Blinatumomab in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis","volume":"6","author":"Locatelli","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.eclinm.2025.103211_bib6","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children's oncology group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103211_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103211_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bjh.12239","article-title":"Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission","volume":"161","author":"Hochberg","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.eclinm.2025.103211_bib9","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021011694","article-title":"How I treat pediatric acute myeloid leukemia","volume":"138","author":"Rubnitz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2025.103211_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MOP.0000000000000855","article-title":"Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy","volume":"32","author":"Elgarten","year":"2020","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.eclinm.2025.103211_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/14737140.2021.1841640","article-title":"Pediatric relapsed acute myeloid leukemia: a systematic review","volume":"21","author":"Hoffman","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.eclinm.2025.103211_bib12","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/bloodadvances.2023012041","article-title":"Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?","volume":"8","author":"Masetti","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.eclinm.2025.103211_bib13","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"24","author":"Jeha","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103211_bib14","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group","volume":"120","author":"Loken","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2025.103211_bib15","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2025.103211_bib16","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/s41375-018-0094-0","article-title":"Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.eclinm.2025.103211_bib17","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2003.06.128","article-title":"Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951","volume":"21","author":"Wells","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103211_bib18","first-page":"1626","article-title":"Cytosine arabinoside and mitoxantrone induction chemotherapy followed by bone marrow transplantation or chemotherapy for relapsed or refractory pediatric acute myeloid leukemia","volume":"8","author":"Wells","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.eclinm.2025.103211_bib19","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103211_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020426","article-title":"Blinatumomab in Children and Adolescents with Relapsed\/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: a Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers","volume":"14","author":"Beneduce","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eclinm.2025.103211_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29715","article-title":"Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia","volume":"69","author":"Locatelli","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2025.103211_bib22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41375-022-01770-3","article-title":"Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL","volume":"37","author":"Locatelli","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.eclinm.2025.103211_bib23","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103211_bib24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103211_bib25","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103211_bib26","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103211_bib27","first-page":"3631","article-title":"Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: development, current status, and future directions","volume":"130","author":"Kantarjian","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2025.103211_bib28","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/pbc.25454","article-title":"Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children's Oncology Group (COG) study ADVL04P2","volume":"62","author":"Raetz","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2025.103211_bib29","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.21.01693","article-title":"Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group Protocol AALL1621","volume":"40","author":"O'Brien","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103211_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/BS9.0000000000000140","article-title":"Immune therapy: a new therapy for acute myeloid leukemia","volume":"5","author":"Tian","year":"2023","journal-title":"Blood Sci"},{"key":"10.1016\/j.eclinm.2025.103211_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415907","article-title":"The latest breakthroughs in immunotherapy for acute myeloid leukemia, with a special focus on NKG2D ligands","volume":"23","author":"Maurer","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eclinm.2025.103211_bib32","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","article-title":"Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"38","author":"Rheingold","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.eclinm.2025.103211_bib33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/hematology.2023000422","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"2023","author":"Epperly","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025001439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025001439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:25:20Z","timestamp":1759425920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025001439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":33,"alternative-id":["S2589537025001439"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103211","relation":{},"ISSN":["2589-5370"],"issn-type":[{"type":"print","value":"2589-5370"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitoxantrone in combination with clofarabine (MITCL) in children, adolescents and young adults with relapsed\/refractory acute leukaemia: final results of a phase I\/II trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103211"}}